To obtain emergency consultation with a medical toxicologist, in the United States, call 1-800-222-1222 for the nearest regional poison control center. Contact information for poison control centers around the world is available at the WHO website and in the UpToDate topic on regional poison control centers (society guideline links). |
History |
|
Clinical manifestations* |
Gastrointestinal (30 minutes to 6 hours)
|
Latent (6 to 24 hours)¶
|
Shock and metabolic acidosis (6 to 72 hours)
|
Hepatotoxicity (12 to 96 hours, severity is dose dependent)
|
Bowel obstruction (2 to 8 weeks, usually gastric outlet obstruction)
|
Diagnosis |
|
Ancillary studies |
Symptomatic
|
Asymptomatic
|
Management |
Supportive care: Support airway, breathing, and circulation; treat hypovolemic shock with fluid boluses of normal saline (10 to 20 mL/kg) as needed |
Gastrointestinal decontamination: The need for gastrointestinal decontamination is determined by the number and location of iron pills seen on plain radiograph of the abdomen:
|
Deferoxamine: We recommend IV deferoxamine for patients with an oral iron overdose and any one of the following signs of serious poisoning:
Prior to administration of deferoxamine, consultation with a medical toxicologist and/or regional poison control center is recommended. For details regarding dose and duration of treatment, refer to UpToDate content on acute iron poisoning. |
BUN: blood urea nitrogen; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CBC: complete blood count; PT: prothrombin time; PTT: partial thromboplastin time; INR: international normalized ratio; IV: intravenous.
* In patients with moderate to severe iron poisoning, the progression of the clinical phases often overlap and may occur rapidly; the clinical phase should be determined by the patient's clinical and laboratory manifestations, not by the time since the ingestion.
¶ It is critical to differentiate patients who are in the latent phase from those with low-toxicity ingestions who have exhibited only mild gastrointestinal symptoms and for whom toxicity has now resolved. Patients whose gastrointestinal symptoms have improved should be observed and re-evaluated to determine whether they have truly recovered or are progressing to further clinical deterioration.
Δ A significant amount of unabsorbed iron is present when the number of pills seen on abdominal radiograph and the elemental iron content of the product ingested have the potential for worsening toxicity based upon patient weight.